EU Taxus Approval, Passive Coating Option Expand Boston Scientific’s Reach
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific projects that European conversion rates from bare-metal to drug-eluting stents will range 20-50% in 2003, as reimbursement trends improve
You may also be interested in...
Dissecting DELIVER: Dosing, Non-Polymer Binding Implicated In Guidant Trial
The role of insufficient dosing in the DELIVER trial evaluating Guidant's Achieve drug-eluting stent will likely emerge in presentations at the American College of Cardiology's annual meeting in Chicago March 30-April 2
Dissecting DELIVER: Dosing, Non-Polymer Binding Implicated In Guidant Trial
The role of insufficient dosing in the DELIVER trial evaluating Guidant's Achieve drug-eluting stent will likely emerge in presentations at the American College of Cardiology's annual meeting in Chicago March 30-April 2
J&J Patent Infringement Suit Aims To Slow Down Boston Scientific Express
Johnson & Johnson's decision to aggressively defend a 15-year-old stent patent against Boston Scientific represents a low-risk/high-reward strategy for J&J in the emerging drug-eluting stent market